Abstract:Abnormal DNA methylation is closely related to cancer initiation and progression, and strategies to assay methyltransferase activity and screen its inhibitors are essential for cancer diagnosis and therapy. In this work, surface plasmon resonance (SPR)-based assay for real-time and sensitive monitoring of DNA methyltransferase activity and screening of its inhibitors was conducted via methylation of double-stranded (ds)-DNA consensus sites and the follow-up p53 protein recognition. The consensus ds-DNA possesses a specific sequence of 5'-CCGG-3' in which the second C base can be methylated by M.SssI methyltransferase (M.SssI MTase) and the methylation process impedes the recognition and cleavage of the ds-DNA by HpaII endonuclease, thus, the attachment of p53 protein leads to remarkable SPR signals. In contrast, inhibition of M.SssI MTase activity by a potent inhibitor leaves the consensus ds-DNA unmethylated, and the cleavage of the ds-DNA by HpaII prevents p53 protein from adsorbing onto the chip surface, leading to tiny SPR signals. The binding affinity (K-D) between p53 protein and the methylated consensus ds-DNA was deduced to be 3.04 nM, evidencing the strong binding capability. Two nucleoside inhibitors of 5-Azacytidine (5-Aza) and 5-aza-2'-deoxycytidine (5-Aza-dC), and a non-nucleoside inhibitor of procaine were examined, and their half-maximal inhibiting concentration (IC50) values were highly comparable with those by other methods. The sensing protocol has been successfully utilized for the assay of M.SssI MTase activity in normal and cancer cell lysates. The proof-of-concept experiments demonstrate that SPR serves as a viable means for sensitive detection of methyltransferase activity and screening of its inhibitors using p53 protein bound to methylation-specific ds-DNA consensus sites.

Protein-Protein Interaction Monitoring and Inhibitors Potency Evaluation Based on Crispr-Cas12a Sensing Platform

P53-MDM2 interaction monitoring and inhibitors potency evaluation based on CRISPR-Cas12a sensing platform

In Situ Monitoring of P53 Protein and MDM2 Protein Interaction in Single Living Cells Using Single-Molecule Fluorescence Spectroscopy.

Dual amplification dynamic DNA network system for CRISPR/Cas12a based p53 gene detection

An Ultra-Sensitive CRISPR-Cas12a and Aptamer-Based Biosensor Utilizing Entropy-driven Catalytic DNA Networks for Precise Detection of DNA Methyltransferase 1

An economical, high-throughput protein-protein interaction modulator drug screening technique based on surface-enhanced Raman scattering

Efficient, specific and direct detection of double-stranded DNA targets using Cas12f1 nucleases and engineered guide RNAs

CRISPR/Cas12a Powered DNA Framework‐Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis

Real-time Surface Plasmon Resonance Monitoring of Site-Specific Phosphorylation of P53 Protein and Its Interaction with MDM2 Protein.

The Facile and Visualizable Identification of Broad-Spectrum Inhibitors of MDM2/p53 Using Co-Expressed Protein Complexes

Dual-channel Surface Plasmon Resonance Monitoring of Intracellular Levels of the P53-Mdm2 Complex and Caspase-3 Induced by MDM2 Antagonist Nutlin-3

High-Fidelity and Simultaneous Sensing of Endogenous Mutant and Wild p53 Proteins for Precise Cancer Diagnosis and Drug Screening

Sensitive Surface Plasmon Resonance Detection of Methyltransferase Activity and Screening of Its Inhibitors Amplified by P53 Protein Bound to Methylation-Specific Ds-Dna Consensus Sites.

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Environment-sensitive turn-on fluorescent probes for p53-MDM2 protein-protein interaction.

Electrochemical Detection of the P53 Gene Using Exponential Amplification Reaction (EXPAR) and CRISPR/Cas12a Reactions

Integrated CRISPR/Cas12a with Terminal Protection Strategy for Homogeneous Protein Assay

The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.

Synthetic Protein-to-DNA Input Exchange for Protease Activity Detection Using CRISPR-Cas12a

A miniaturized sandwich immunoassay platform for the detection of protein-protein interactions

PAM-independent ultra-specific activation of CRISPR-Cas12a via sticky-end dsDNA